HK’s Haitong leads Series B funding for US biotech firm Orig3n

Orig3n CEO Robin Smith and COO Kate Blanchard. Photo from Facebook page of Orig3n.

Hong Kong-based Haitong International Securities Group (Haitong), one of the largest Chinese investment banks in offshore markets, has led the initial close of Series B financing in Boston-based biotech research firm Orig3n.

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at